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Purpose. To describe a patient who developed bilateral, simultaneous nonarteritic anterior ischemic optic neuropathy (NAION)
after ingestion of Sildenaﬁl citrate (Viagra) for erectile dysfunction. Methods.O b s e r v a t i o n a lc a s er e p o r t .Results. A 60-year-old
diabetic man noted sudden decrease of vision in both eyes 16 hours after his third consecutive 50mg daily Sildenaﬁl ingestion. A
diagnosis of bilateral NAION was made and he was treated for three days with methylprednisolone 1 g/d intravenously, followed
by oral prednisone 75mg/d. Final visual acuity was 20/50 right eye (OD) and 20/20 left eye (OS). He had preexisting diabetes.
Conclusion. This is the ﬁrst reported case of simultaneous bilateral NAION occurred in a diabetic patient early after Sildenaﬁl
intake. Patients with predisposing conditions such as diabetes have to be warned against the use of PDE inhibitors.
1.Introduction
Sildenaﬁl citrate (Viagra, Pﬁzer Pharmaceuticals, New York,
NY) inhibits selectively cyclic guanosine monophosphate
(cGMP) speciﬁc phosphodiesterase type 5 (PDE 5) and
is used to treat erectile dysfunction. Sildenaﬁl is able, by
enhancing the eﬀect of nitric oxide and cGMP pathway, to
lead to smooth muscle relaxation in the corpus cavernosum,
allowing inﬂow of blood during sexual stimulation. PDE-5
inhibitors have been reported to cause transient changes in
colour perception (objects have blue or blue-green tinges)
or changes in lightness perception (usually an increased
sensitivity), blurred vision, and transitory ERG changes
[1]. Possible additional ocular side eﬀects associated with
Sildenaﬁl or other PDE 5 inhibitors such as Vardenaﬁl
and Tadalaﬁl use are mydriasis, retinal vascular accidents,
conjunctival hyperemia, ocular pain, subconjunctival hem-
orrhage, and ischemic optic neuropathy [1]. With regard
to severe ocular adverse eﬀects, PDE-5-inhibitors-associated
nonarteritic anterior ischemic optic neuropathy (NAION)
has been reported in 49 subjects. Forty-four are related with
the use of Sildenaﬁl, 4 with the use of Tadalaﬁl, and 1 with
the use of Vardenaﬁl [2–7]. Few bilateral sequential cases
have been reported. More recently, Moschos and Margetis
described a single case with bilateral simultaneous anterior
ischaemic optic neuropathy which occurred in a man with
unremarkablemedicalhistory8monthsaftercontinuoususe
of Sildenaﬁl [7].
The purpose of the present case report is to describe a
diabetic patient who developed a simultaneous bilateral
NAIONearlyafteringestionofSildenaﬁlforerectiledysfunc-
tion.
2.CaseReport
A 60-year-old diabetic man took one 50mg tablet of Silde-
naﬁl in the evening for 2 consecutive days without any eﬀects
and he was unable to have intercourse. On the third day
he discontinued antiglycaemic medications, took another
50mg tablet and engaged in sexual activity. Sixteen hours
later he noted sudden decrease of vision in both eyes with
a pronounced worsening in the right eye. He was admitted in
a nearby hospital where a CT brain and a chest radiography
wereperformed.Theywereunremarkableaswellascomplete
blood count and the erythrocyte sedimentation rate. His
medical history was signiﬁcant for noninsulin-dependent di-
abetes for 7 months and his medication was metformin. He
was discharged from hospital with a new prescription of
100mg daily aspirin.2 Case Reports in Medicine
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Figure 1: Color fundus photo of OD (a) and OS (b) with optic disc edema and peripapillary nerve ﬁber layer hemorrhages (a, b) and
peripapillary cotton wool spots (b).
Figure 2: Optical coherence tomography shows subretinal ﬂuid in
the macula in OD.
Seven days after the onset of symptoms, the patient was
hospitalized atour department. Visualacuity was20/63 right
eye (OD) and 20/32 left eye (OS). On fundus examina-
tion, optic disc edema and peripapillary nerve ﬁber layer
hemorrhages were disclosed in both eyes (Figure 1). Serous
macular detachment was present in OD (Figure 2)w h e r e a s
peripapillary cotton wool spots were found in OS. No evi-
dence of diabetic retinopathy was noted. Blood pressure was
withinnormallimitduringtheadmissionperiod.Humphrey
visual ﬁeld testing showed superior altitudinal and central
defects OD and inferior altitudinal defect OS (Figure 3).
A ﬂuorescein angiogram showed late leakage in the optic
disc of both eyes (Figure 4). Symptoms of giant cell arteritis
were not present and no relative aﬀerent pupillary defect
was detected. A diagnosis of bilateral NAION was made
and he was treated for three days with methylprednisolone
1g/d intravenously, followed by oral prednisone 75mg/d.
The prednisone dose was tapered and discontinued over one
month. Two weeks after the last steroid i.v. administration,
visual acuity had increased to 20/50 OD and 20/20 OS. Optic
discedema,sub-retinalﬂuidandserousmaculardetachment
resolved in OD and optic disc edema improved in OS. No
sign of dye leakage of the optic disc was found in eyes and
visual ﬁeld testing disclosed altitudinal defects in both eyes.
Threemonthslater,visualacuitywasstableandtheopticdisc
was pale in OD.
3. Discussion
The incidence of bilateral AION reported in the general
population varies from 10.5% to 73% [8]. This wide
variation is due to a number of factors such as the retro-
spective retrieval of data in almost all studies and the length
and quality of followup. In the Ischemic Optic Neuropathy
Decompression Trial (IONDT) Followup Study [9], new
NAION in the fellow eye occurred in 14.7% of patients at
risk during a median followup of 5.1 years. In a prospective
study by Beri et al. [8], the estimated 25th-percentile time
to bilaterality from the onset of AION in the ﬁrst eye in
NAION patients was 32.4 months and it decreased to 17.6
months in the group matched with our patient by sex and
age (45–64 years) and to 9.8 months in the diabetes group.
Bilateral simultaneous anterior ischemic optic neuropathy is
rare. Shibayama et al. [10] reported a case of bilateral and
nearly simultaneously occurring NAION in a 61-year-old
man. The patient had two of the established risk factors for
NAION such as a poorly controlled diabetes and a small disc
with a small physiologic cup. Bilateral simultaneous NAION
a f t e rS i l d e n a ﬁ lh a sb e e np r e v i o u s l yr e p o r t e di na5 5 - y e a r -
old man with an unremarkable medical history 8 months
after continuous use of Sildenaﬁl 4-5 times a month [7].
The authors did not disclose whether the patient developed
bilateral simultaneous NAION soon after ingesting the drug.
Sexual stimulation triggers the release of nitric oxide
(NO) from noncholinergic, nonadrenergic nerve endings
and from endothelial cells of arteries and sinusoids of
corpuscavernosum.NOactivatesguanylylcyclasetoincrease
intracellular cGMP production that produces relaxation of
the corpus cavernosum and penile arteriolar smooth muscle
determining a subsequent erection. Sildenaﬁl inhibits phos-
phodiesterasetype5andthisresultsinhigherconcentrations
of cGMP that activates cGMP-dependent protein kinase
(PKG).
Studies on the ocular circulation in healthy subjects sup-
port the involvement of endogenous NO derived from either
endothelial cells or perivascular nitrergic neurons in the
control of vascular smooth muscle tone. A suﬃcient blood
supply in the ocular circulation requires the maintenance of
a basal vasodilator tone in ocular arteries. Like in many other
arterial beds, this is provided by a constant formation of NO.
A dysbalance of the NO-system contributes to alterations
in systemic vascular diseases like hypertension or diabetes,Case Reports in Medicine 3
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Figure 3: Test results of Humphrey visual ﬁeld. Superior altitudinal and central defects OD (a) and inferior altitudinal defect OS (b).
(a) (b)
Figure 4: Fluorescein angiography shows late dye leakage in both eyes (a, b).4 Case Reports in Medicine
where basal formation of NO as well as NO dependent
vasodilatation is impaired.
Human and animal studies suggest that alterations of
the NO system in part mediate blood ﬂow changes in states
of hyperglycemia. High glucose (500mg/dL) signiﬁcantly
decreased nitrite production compared with normal glucose
(100mg/dL) whereas PKG activator treatment induced high
level of NO, inducible nitric oxide synthase and PKG in
high glucose-incubated cells [11]. Therefore, a situation of
hyperglycemia and PKG activation may be characterized by
an enhancement of the NO-pathway. It is noteworthy to
mention that our patient was able to have intercourse only
on the third day after he took Sildenaﬁl and avoided his
oral medications for diabetes with consequent presumed
secondary hyperglycemia. It is also interesting to underline
that not only concentrations of NO are elevated in the
vitreous of patients with proliferative diabetic retinopathy
but one of the nitric oxide synthase (NOS) byproducts is
increased in aqueous humor of diabetic patients with or
without diabetic retinopathy indicating that NOS activity is
already increased in early stages of insulin resistance such as
in type 2 diabetes mellitus. NO as well as hypoxia is reported
to upregulate the vascular endothelial growth factor (VEGF)
gene, although there are some reports on the negative eﬀects
of NO on VEGF activity. These conﬂicting data of NO
eﬀects may be attributed mainly to the amount of released
NO. Indeed, NO can be a positive or negative modulator
of the VEGF gene under the same conditions simply by
changing its amounts [12]. NO is capable of stimulating
angiogenesis and vascular permeability via interplay with
VEGF. Since intravenous administration of VEGF to experi-
mentalanimalsincreasedendothelialpermeabilityandblood
ﬂowinretina,choroid,andanterioruvea,itsacuteexpression
may result in damaging edema and secondary injury during
NAION.
Phosphodiesterase 5inhibitors, inthecardiovascularsys-
tem, reduce arterial systemic blood pressure and, as regard-
ing the hemodynamic eﬀect on ocular circulation, it is
known that Sildenaﬁl signiﬁcantly increases, rather than de-
creases, blood ﬂow velocity in the retrobulbar and choroidal
circulation. Other mechanisms have to be further investi-
gated. In patients with a predisposing diabetic condition,
SildenaﬁlintakecancausechangesinNObalancealteringthe
normal vascular autoregulation so that the ocular circulation
may not be able to compensate for a drop in systemic blood
pressure. Moreover, the indirect involvement of Sildenaﬁl in
the NO system with eﬀects on inducible NO synthase and
the VEGF signaling pathway may lead to leukocyte vascular
adhesion, downregulation of tight junction protein, and
breakdown of the blood-ocular barrier leading to NAION
damages.
A new class of hydrogen sulﬁde (H(2)S)-donating hy-
brids combined with sildenaﬁl might show improved tolera-
bility with potential cytoprotective eﬀect of H(2)S on retinal
neurons [13, 14].
OurpatientpresentednotonlywithbilateralNAIONbut
also with serous macular detachment in the OD that has
been previously reported [15] due to the vasodilator action
of Sildenaﬁl that causes an idiosyncratic engorgement of the
choroidal vasculature leading to leakage across the retinal
pigment epithelium and accumulation of subretinal ﬂuid.
This is the second reported case of bilateral simultaneous
NAION in a Sildenaﬁl consumer. Diﬀerently from the case
described by Moschos and Margetis [7] ,o u rc a s ei sc h a r -
acterized by the sporadic use of Sildenaﬁl, the occurrence
of the neuropathy early after Sildenaﬁl ingestion, and the
association with diabetes which is a recognized risk factor for
vascular accidents.
In conclusion we believe that general practitioners and
neuroophthalmologists should recommend against the use
of PDE inhibitors not only in patients who have already
experienced an episode of NAION in one eye, as stated
by the European Supplementary Protection Certiﬁcate class
labelling, or have a small disc-at-risk, but also in patients
with predisposing systemic vascular diseases like hyperten-
sion or diabetes.
A phase IV observational case-crossover study to as-
sess whether PDE 5 inhibitors increase the chance of
triggering the onset of acute NAION is currently ongoing
(http://www.clinicaltrials.gov/ct2/show/NCT00759174?term
=naion&rank=1), and the results are expected to be available
in the near future and will provide useful data on the safety
of these compounds and on patients at risk who should
avoid their use.
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